Current Oncology Reports

, Volume 14, Issue 6, pp 483–485

Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?

Invited Commentary


Ovarian cancer Poly(adenosine diphosphate ribose) polymerase inhibitors Survival End point Olaparib Bevacizumab 


  1. 1.
  2. 2.
    Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Sjoquist KM, Lee C, Lord S, et al. Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC). J Clin Oncol. 2012;30. suppl; abstr 5081.Google Scholar
  5. 5.
    Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30:1030–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.PubMedCrossRefGoogle Scholar
  8. 8.
    Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Pujade-Lauraine E, Hilpert F, Weber B, et al: AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol (suppl; abstr LBA5002^), 2012.Google Scholar
  10. 10.
    Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Ang JE, Gourley C, High HA, et al. Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: a multi-institutional study. J Clin Oncol. 2012;30. suppl; abstr 5022.Google Scholar
  12. 12.
    Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Sridhara R, Johnson JR, Justice R, et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst. 2010;102:230–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Gynaecology Unit, The Royal Marsden NHS Foundation TrustLondonUK
  2. 2.Division of Clinical StudiesInstitute of Cancer ResearchLondonUK

Personalised recommendations